Validity of prostate health index and percentage of [-2] pro-prostate-specific antigen as novel biomarkers in the diagnosis of prostate cancer: omani tertiary hospitals experience

Safana S., Al Saidi; Nafila B., Al Riyami; Mohammed S., Al Marhoon; Mohammed S., Al Saraf; Salim S., Al Busaidi; Waad Allah S., Mula Abed; Riad, Bayoumi

Safana S., Al Saidi; Nafila B., Al Riyami; Mohammed S., Al Marhoon; Mohammed S., Al Saraf; Salim S., Al Busaidi; Waad Allah S., Mula Abed; Riad, Bayoumi.

Oman Medical Journal. 2017; 26 (3): 275-283

in English | IMEMR | ID: emr-188544

ABSTRACT

ABSTRACT

Objectives:

Prostate cancer is the leading cancer in older men. The Ministry of Health Oman Cancer Incidence Registry 2013 lists cancer of the prostate as the first most common cancer in males. Therefore, early detection is important and prostate-specific antigen [PSA] is widely used as an established laboratory test. However, despite its wide use, its value in screening, particularly in asymptomatic males, is controversial when considering the risks and benefits of early detection

Subject(s)

Humans; Male; Middle Aged; Aged; Aged, 80 and over; Prostate-Specific Antigen; Prospective Studies; Early Detection of Cancer; Neoplasm Grading; Biopsy; Tertiary Care Centers

Search on Google

XML

Index: IMEMR (Eastern Mediterranean) Main subject: Biopsy / Prospective Studies / Prostate-Specific Antigen / Early Detection of Cancer / Neoplasm Grading / Tertiary Care Centers Type of study: Screening study Limits: Aged / Humans / Male Language: English Journal: Oman Med. J. Year: 2017

Similar

MEDLINE

LILACS

LIS

Search on Google

XML